Avidity Biosciences, Inc. (RNA)
NASDAQ: RNA · Real-Time Price · USD
72.50
+0.04 (0.05%)
Jan 29, 2026, 9:57 AM EST - Market open
Avidity Biosciences Employees
Avidity Biosciences had 391 employees as of December 31, 2024. The number of employees increased by 138 or 54.55% compared to the previous year.
Employees
391
Change (1Y)
138
Growth (1Y)
54.55%
Revenue / Employee
$53,371
Profits / Employee
-$1,406,105
Market Cap
10.92B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 391 | 138 | 54.55% |
| Dec 31, 2023 | 253 | 67 | 36.02% |
| Dec 31, 2022 | 186 | 61 | 48.80% |
| Dec 31, 2021 | 125 | 54 | 76.06% |
| Dec 31, 2020 | 71 | 35 | 97.22% |
| Jun 30, 2020 | 42 | - | - |
| Mar 31, 2020 | 36 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Bio-Techne | 3,100 |
| BioMarin Pharmaceutical | 3,040 |
| Jazz Pharmaceuticals | 2,800 |
| Exelixis | 1,147 |
| Ionis Pharmaceuticals | 1,069 |
| Axsome Therapeutics | 816 |
| Arrowhead Pharmaceuticals | 711 |
| Madrigal Pharmaceuticals | 528 |
RNA News
- 17 hours ago - Sonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product Development - Accesswire
- 13 days ago - Pharma sector doubles down on AI amid hopes of slashing costs, timelines - Reuters
- 6 weeks ago - Top 2 Health Care Stocks That May Keep You Up At Night In December - Benzinga
- 2 months ago - These 15 stocks are still showing momentum — and a market-beating edge - Market Watch
- 2 months ago - Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44 - PRNewsWire
- 2 months ago - Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights - PRNewsWire
- 3 months ago - 3 Investable Laggards In An Overbought Market - Seeking Alpha
- 3 months ago - Avidity Biosciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avidity Biosciences, Inc. - RNA - Business Wire